Conflict of interest statement: S. Sun reports grants from NCI, Terri Brodeur 
Breast Cancer Foundation, and Massachusetts General Hospital during the conduct 
of the study. I. Leshchiner reports personal fees from PACT Pharma, Inc and 
Enov1, LLC outside the submitted work. A. Kambadakone reports grants from 
Philips Healthcare, GE Healthcare, PanCAN, personal fees from Bayer, and other 
support from Siemens Healthcare outside the submitted work. S.J. Isakoff reports 
personal fees from Immunomedics, Mylan, Myriad, Puma, Novartis, Seattle 
Genetics, grants and personal fees from OncoPep and AbbVie, grants from Merck, 
AstraZeneca, and Genentech outside the submitted work. D. Juric reports grants 
and personal fees from Novartis, Genentech, Syros, grants from Pfizer, Takeda, 
personal fees from Relay, PIC Therapeutics, Mapkure, Vibliome, grants and 
personal fees from Eisai, grants from InventisBio, Arvinas, Ribon Therapeutics, 
and Infinity Pharmaceuticals outside the submitted work. G. Getz reports grants 
from IBM during the conduct of the study; and receives research funds from 
Pharmacyclics. G. Getz is a founder, consultant, and holds privately held equity 
in Scorpion Therapeutics. A. Bardia reports grants from Genentech, Novartis, 
Pfizer, Merck, Sanofi, Radius Health, Immunomedics, and Diiachi 
Pharma/AstraZeneca, and personal fees from Pfizer, Novartis, Genentech, Merck, 
Radius Health, Immunomedics, Taiho, Sanofi, Diiachi Pharma/AstraZeneca, Puma; 
Biothernostics Inc., Phillips, Eli Lilly, Foundation Medicine, during the 
conduct of the study; personal fees from Pfizer, Novartis, Genentech, Merck, 
Radius Health, Immunomedics, Taiho, Sanofi, Diiachi Pharma/AstraZeneca, Puma; 
Biothernostics Inc., Phillips, Eli Lilly, Foundation Medicine, and grants from 
Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, and 
Diiachi Pharma/AstraZeneca outside the submitted work. L.W. Ellisen reports 
grants from DOD/CDMRP and other support from Tracey Davis Memorial Fund during 
the conduct of the study; and sacituzumab (drug only) provided by the sponsor 
for in vitro experiments as acknowledged in the manuscript. No disclosures were 
reported by the other authors.